Safety and efficacy of rituximab in childhood-onset systemic lupus erythematosus and other rheumatic diseases

Journal of Rheumatology

Volumn 42, Issue 3, 2015, Pages 541-546

  Tambralli, Ajay ^a   Beukelman, Timothy ^b   Cron, Randy Quentin ^b   Stoll, Matthew Laurence ^b  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

Pediatrics; Rituximab; Systemic lupus erythematosus; Treatment

Indexed keywords

ALBUMIN; AZATHIOPRINE; CD19 ANTIGEN; CORTICOSTEROID; CREATININE; CYCLOPHOSPHAMIDE; DIPHENHYDRAMINE; ETANERCEPT; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PARACETAMOL; PREDNISONE; RITUXIMAB; ANTIRHEUMATIC AGENT;

ABSCESS; ANAPHYLACTOID PURPURA; ANCA ASSOCIATED VASCULITIS; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BLOOD CELL COUNT; CELLULITIS; CHILD; CHILDHOOD DISEASE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DERMATOMYOSITIS; DISEASE ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE SEDIMENTATION RATE; ESCHERICHIA COLI INFECTION; FEBRILE NEUTROPENIA; FEMALE; FEVER; HERPES ZOSTER; HERPES ZOSTER OPHTHALMICUS; HUMAN; INCIDENCE; INFUSION RELATED REACTION; JUVENILE RHEUMATOID ARTHRITIS; LUNG ASPERGILLOSIS; LUNG HEMOSIDEROSIS; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MIXED CONNECTIVE TISSUE DISEASE; MUCOSA INFLAMMATION; NECROTIZING FASCIITIS; ONSET AGE; OPPORTUNISTIC INFECTION; PERITONITIS; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRIORITY JOURNAL; PYELONEPHRITIS; RETROSPECTIVE STUDY; RHEUMATIC DISEASE; SJOEGREN SYNDROME; STAPHYLOCOCCAL BACTEREMIA; STREPTOCOCCUS PNEUMONIA; SYNDROME CREST; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULITIS; VOMITING; ADOLESCENT; LUPUS ERYTHEMATOSUS, SYSTEMIC; PRESCHOOL CHILD; RHEUMATIC DISEASES; TREATMENT OUTCOME;

ADOLESCENT; ANTIRHEUMATIC AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; RETROSPECTIVE STUDIES; RHEUMATIC DISEASES; RITUXIMAB; TREATMENT OUTCOME;

EID: 84923901962     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.140863     Document Type: Article

References (25)

1. Alexeeva EI, Valieva SI, Bzarova TM, Semikina EL, Isaeva KB, Lisitsyn AO, et al. Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis. Clin Rheumatol 2011;30:1163-72.
2. Cooper MA, Willingham DL, Brown DE, French AR, Shih FF, White AJ. Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients. Arthritis Rheum 2007;56:3107-11.
3. Jansson AF, Sengler C, Kuemmerle-Deschner J, Gruhn B, Kranz AB, Lehmann H, et al. B cell depletion for autoimmune diseases in paediatric patients. Clin Rheumatol 2011;30:87-97.
4. Kavcic M, Fisher BT, Seif AE, Li Y, Huang YS, Walker D, et al. Leveraging administrative data to monitor rituximab use in 2875 patients at 42 freestanding children's hospitals across the United States. J Pediatr 2013;162:1252-8, 1258 e1.
5. Lehman TJ, Singh C, Ramanathan A, Alperin R, Adams A, Barinstein L, et al. Prolonged improvement of childhood onset systemic lupus erythematosus following systematic administration of rituximab and cyclophosphamide. Pediatr Rheumatol Online J 2014;12:3.
6. Watson L, Beresford MW, Maynes C, Pilkington C, Marks SD, Glackin Y, et al. The indications, efficacy and adverse events of rituximab in a large cohort of patients with juvenile-onset SLE. Lupus 2015;24:10-7.
7. Kamphuis S, Silverman ED. Prevalence and burden of pediatric-onset systemic lupus erythematosus. Nat Rev Rheumatol 2010;6:538-46.
8. McCurdy DK, Lehman TJ, Bernstein B, Hanson V, King KK, Nadorra R, et al. Lupus nephritis: prognostic factors in children. Pediatrics 1992;89:240-6.
9. Contreras G, Lenz O, Pardo V, Borja E, Cely C, Iqbal K, et al. Outcomes in African Americans and Hispanics with lupus nephritis. Kidney Int 2006;69:1846-51.
10. Nwobi O, Abitbol CL, Chandar J, Seeherunvong W, Zilleruelo G. Rituximab therapy for juvenile-onset systemic lupus erythematosus. Pediatr Nephrol 2008;23:413-9.
11. Willems M, Haddad E, Niaudet P, Kone-Paut I, Bensman A, Cochat P, et al. Rituximab therapy for childhood-onset systemic lupus erythematosus. J Pediatr 2006;148:623-7.
12. Marks SD, Patey S, Brogan PA, Hasson N, Pilkington C, Woo P, et al. B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum 2005;52:3168-74.
13. Kumar S, Benseler SM, Kirby-Allen M, Silverman ED. B-cell depletion for autoimmune thrombocytopenia and autoimmune hemolytic anemia in pediatric systemic lupus erythematosus. Pediatrics 2009;123:e159-63.
14. Trachana M, Koutsonikoli A, Farmaki E, Printza N, Tzimouli V, Papachristou F. Safety and efficacy of rituximab in refractory pediatric systemic lupus erythematosus nephritis: a single-center experience of Northern Greece. Rheumatol Int 2013;33:809-13.
15. Ale'ed A, Alsonbul A, Al-Mayouf SM. Safety and efficacy of combined cyclophosphamide and rituximab treatment in recalcitrant childhood lupus. Rheumatol Int 2014;34:529-33.
16. Record JL, Beukelman T, Cron RQ. High prevalence of myositis in a southeastern United States pediatric systemic lupus erythematosus cohort. Pediatr Rheumatol Online J 2011;9:20.
17. Leandro MJ, Cambridge G, Edwards JC, Ehrenstein MR, Isenberg DA. B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology 2005;44:1542-5.
18. FitzGerald JD, Grossman JM. Validity and reliability of retrospective assessment of disease activity and flare in observational cohorts of lupus patients. Lupus 1999;8:638-44.
19. Costa-Reis P, Nativ S, Isgro J, Rodrigues T, Yildirim-Toruner C, Starr A, et al. Major infections in a cohort of 120 patients with juvenile-onset systemic lupus erythematosus. Clin Immunol 2013;149:442-9.
20. Opastirakul S, Chartapisak W. Infection in children with lupus nephritis receiving pulse and oral cyclophosphamide therapy. Pediatr Nephrol 2005;20:1750-5.
21. Vachvanichsanong P, Dissaneewate P, McNeil E. Intravenous cyclophosphamide combined with steroids in pediatric onset severe lupus nephritis. Int Urol Nephrol 2013;45:1301-8.
22. Lehman TJ, Onel K. Intermittent intravenous cyclophosphamide arrests progression of the renal chronicity index in childhood systemic lupus erythematosus. J Pediatr 2000;136:243-7.
23. Barbano G, Gusmano R, Damasio B, Alpigiani MG, Buoncompagni A, Gattorno M, et al. Childhood-onset lupus nephritis: a single-center experience of pulse intravenous cyclophosphamide therapy. J Nephrol 2002;15:123-9.
24. Moroni G, Raffiotta F, Trezzi B, Giglio E, Mezzina N, Del Papa N, et al. Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study. Rheumatology 2014;53:1570-7.
25. Kang KY, Kwok SK, Ju JH, Park KS, Cho CS, Kim HY, et al. The causes of death in Korean patients with systemic lupus erythematosus over 11 years. Lupus 2011;20:989-97.